Is Dysfunction of Caveolin-1 a Link Between Systemic Sclerosis and Breast Cancer, Opening a Window on Both Etiologies?

Archives of Medical Research

Volumn 41, Issue 4, 2010, Pages 297-301

  Qian, Niansong ^a,b,c   Ueno, Takayuki ^a  

^a KYOTO UNIVERSITY   (Japan)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c BEIJING 302 HOSPITAL   (China)

Author keywords

Breast cancer; Caveolin 1; Systemic sclerosis; TGF

Indexed keywords

CAVEOLIN 1; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

BREAST CANCER; CANCER PATIENT; CARCINOGENESIS; DISEASE ASSOCIATION; GENE CONTROL; GENETIC DISORDER; HUMAN; LUNG FIBROSIS; MAMMOGRAPHY; NONHUMAN; NOTE; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; RISK FACTOR; SIGNAL TRANSDUCTION; SYSTEMIC SCLEROSIS; BREAST NEOPLASMS; FEMALE; PATHOPHYSIOLOGY; PHYSIOLOGY; SCLERODERMA, SYSTEMIC;

BREAST NEOPLASMS; CAVEOLIN 1; FEMALE; HUMANS; SCLERODERMA, SYSTEMIC;

EID: 77954630974     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2010.05.009     Document Type: Note

References (43)

1. Chifflot H., Fautrel B., Sordet C., et al. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum 2008, 37:223-235.
2. Pontifex E.K., Hill C.L., Roberts-Thomson P. Risk factors for lung cancer in patients with scleroderma: a nested case-control study. Ann Rheum Dis 2007, 66:551-553.
3. Derk C.T., Rasheed M., Artlett C.M., et al. A cohort study of cancer incidence in systemic sclerosis. J Rheumatol 2006, 33:1113-1116.
4. Derk C.T. Associations of breast cancer development in patients with systemic sclerosis: an exploratory study. Clin Rheumatol 2007, 26:1615-1619.
5. Martin L.J., Boyd N.F. Mammographic density. Potential mechanisms of breast cancer risk associated with mammographic density: hypotheses based on epidemiological evidence. Breast Cancer Res 2008, 10:201.
6. Oliver J.E., Silman A.J. Why are women predisposed to autoimmune rheumatic diseases?. Arthritis Res Ther 2009, 11:252.
7. Oliver J.E., Silman A.J. What epidemiology has told us about risk factors and aetiopathogenesis in rheumatic diseases. Arthritis Res Ther 2009, 11:223.
8. Lambe M., Björnådal L., Neregård P., et al. Childbearing and the risk of scleroderma: a population-based study in Sweden. Am J Epideimol 2004, 15(159):162-166.
9. Artlett C.M., Rasheed M., Russo-Stieglitz K.E., et al. Influence of prior pregnancies on disease course and cause of death in systemic sclerosis. Ann Rheum Dis 2002, 61:346-350.
10. Tuma R. Mimicking pregnancy to reduce breast cancer risk. J Natl Cancer Inst 2010, 21:517-518.
11. Tan F.K., Arnett F.C. Genetic factors in the etiology of systemic sclerosis and Raynaud phenomenon. Curr Opin Rheumatol 2000, 12:511-519.
12. Tan F.K., Wang N., Kuwana M., et al. Association of fibrillin 1 single-nucleotide polymorphism haplotypes with systemic sclerosis in Choctaw and Japanese populations. Arthritis Rheum 2001, 44:893-901.
13. Hoshi M., Yasuoka H., Kuwana M. Estrogen receptor gene polymorphisms in Japanese patients with systemic sclerosis. Clin Exp Rheumatol 2008, 26:914-917.
14. Tourkina E., Gooz P., Pannu J., et al. Opposing effects of protein kinase C alpha and protein kinase C epsilon on collagen expression by human lung fibroblasts are mediated via MEK/ERK and caveolin-1 signaling. J Biol Chem 2005, 280:13879-13887.
15. Drab M., Verkade P., Elger M., et al. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 2001, 28(293):2449-2452.
16. Razani B., Engelman J.A., Wang X.B., et al. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem 2001, 12:38121-38138.
17. Odajima N., Betsuyaku T., Nasuhara Y., et al. Loss of caveolin-1 in bronchiolization in lung fibrosis. J Histochem Cytochem 2007, 55:899-909.
18. Galdo F.D., Sotgia F., de Almeida C.J., et al. Decreased expression of caveolin 1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis. Arthritis Rheum 2008, 58:2854-2865.
19. Compston A., Coles A. Multiple sclerosis. Lancet 2008, 25(3729):1502-1517.
20. Achiron A., Barak Y., Gail M., et al. Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments. Breast Cancer Res Treat 2005, 89:265-270.
21. Shin T., Kim H., Jin J.K., et al. Expression of caveolin-1, -2, and -3 in the spinal cords of Lewis rats with experimental autoimmune encephalomyelitis. J Neuroimmunol 2005, 165:11-20.
22. Heshmati Y., Mirabzadeh A., Feizzade G., et al. A novel polymorphic purine complex at the 1.5 kb upstream region of the human caveolin-1 gene and risk of Alzheimer's disease; extra-short alleles and accumulated allele homozygosity. Am J Med Genet B Neuropsychiatr Genet 2009, 5(150B):248-253.
23. Zarif Yeganeh M., Mirabzadeh A., Khorram Khorshid H.R., et al. Novel extreme homozygote haplotypes at the human caveolin 1 gene upstream purine complex in sporadic Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 2010, 5(153B):347-349.
24. Zarif Yeganeh M., Ghaffarpour M., Farhud D.D., et al. Skew in the human caveolin 1 gene upstream purine complex homozygote haplotype compartment in multiple sclerosis. J Neuroimmunol 2009, 30(216):103-107.
25. Mori Y., Chen S.J., Varga J. Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. Arthritis Rheum 2003, 48:1964-1978.
26. Sotgia F., Rui H., Bonuccelli G., et al. Caveolin-1, mammary stem cells, and estrogen-dependent breast cancers. Cancer Res 2006, 15(66):10647-10651.
27. Fu M., Wang C., Li Z., et al. Cyclin D1: normal and abnormal functions. Endocrinology 2004, 145:5439-5447.
28. Zhang W., Razani B., Altschuler Y., et al. Caveolin-1 inhibits epidermal growth factor-stimulated lamellipod extension and cell migration in metastatic mammary adenocarcinoma cells (MTLn3). Transformation suppressor effects of adenovirus-mediated gene delivery of caveolin-1. J Biol Chem 2000, 275:20717-20725.
29. Williams T.M., Medina F., Badano I., et al. Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo: role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J Biol Chem 2004, 279:51630-51646.
30. Witkiewicz A.K., Dasgupta A., Sotgia F., et al. An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol 2009, 174:2023-2034.
31. Witkiewicz A.K., Dasgupta A., Nguyen K.H., et al. Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancer. Cancer Biol Ther 2009, 8:1071-1079.
32. Williams T.M., Sotgia F., Lee H., et al. Stromal and epithelial caveolin-1 both confer a protective effect against mammary hyperplasia and tumorigenesis: caveolin-1 antagonizes cyclin D1 function in mammary epithelial cells. Am J Pathol 2006, 169:1784-1801.
33. Sotgia F., Schubert W., Pestell R.G., et al. Genetic ablation of caveolin-1 in mammary epithelial cells increases milk production and hyper-activates STAT5a signaling. Cancer Biol Ther 2006, 5:292-297.
34. Thiery J.P., Sleeman J.P. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 2006, 7:131-142.
35. Vincan E., Barker N. The upstream components of the Wnt signalling pathway in the dynamic EMT and MET associated with colorectal cancer progression. Clin Exp Metastasis 2008, 25:657-663.
36. Yamauchi Y., Kohyama T., Takizawa H., et al. Tumor necrosis factor-alpha enhances both epithelial-mesenchymal transition and cell contraction induced in A549 human alveolar epithelial cells by transforming growth factor-beta1. Exp Lung Res 2010, 36:12-24.
37. Sotgia F., Williams T.M., Schubert W., et al. Caveolin-1 deficiency (-/-) conveys premalignant alterations in mammary epithelia, with abnormal lumen formation, growth factor independence, and cell invasiveness. Am J Pathol 2006, 168:292-309.
38. Chambaz E.M., Souchelnitskiy S., Pellerin S., et al. Transforming growth factors-beta s: a multifunctional cytokine family. Implication in the regulation of adrenocortical cell endocrine functions. Horm Res 1996, 45:222-226.
39. Massagué J. How cells read TGF-beta signals. Nat Rev Mol Cell Biol 2000, 1:169-178.
40. Hoodless P.A., Wrana J.L. Mechanism and function of signaling by the TGF beta superfamily. Curr Top Microbiol Immunol 1998, 228:235-272.
41. Macías-Silva M., Abdollah S., Hoodless P.A., et al. MADR2 is a substrate of the TGFbeta receptor and its phosphorylation is required for nuclear accumulation and signaling. Cell 1996, 27(87):1215-1224.
42. Razani B., Zhang X.L., Bitzer M., et al. Caveolin-1 regulates transforming growth factor (TGF)-beta/SMAD signaling through an interaction with the TGF-beta type I receptor. J Biol Chem 2001, 276:6727-6738.
43. Jasmin J.F., Mercier I., Dupuis J., et al. Short-term administration of a cell-permeable caveolin-1 peptide prevents the development of monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy. Circulation 2006, 114:912-920.